A 57-year-old man with metastatic colorectal cancer, a left internal jugular port, and reported apixaban use presented to the emergency department with worsening unilateral left upper-extremity swelling. Overnight point-of-care ultrasound did not identify a definite deep venous thrombosis (DVT), and he was discharged with next-morning formal imaging because formal vascular ultrasound was unavailable overnight. Formal imaging later that same day showed axillary thrombosis, and contrast CT of the...

No abstract

No abstract

Bats have been increasingly recognized to host relapsing fever borreliae as well as borreliae that form novel clades adjacent to the Lyme borreliosis group. However, the genetic diversity and zoonotic potential of bat-borne borreliae remain poorly understood, in part because most work to date has focused on bats in the tropics. Fewer bat-borne Borrelia surveys have been conducted in temperate zones, where many bats undertake seasonal migrations that may facilitate pathogen dispersal. We surveyed...

Ziftomenib - a potent, selective, oral menin inhibitor - is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of ziftomenib in combination with standard therapies for R/R and newly diagnosed AML. Here, we report outcomes of adults with R/R NPM1-m AML treated with ziftomenib plus venetoclax/azacitidine. In phase 1a, patients received ziftomenib 200, 400, or...